Chaewon Park

The Anti-Inflammatory Activities of Fermented Curcuma That Contains Butyrate Mitigate DSS-Induced Colitis in Mice

B. Lim, Da Hee Kim, A. B. Bayazid, 2022, Molecules.

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer

You Won Lee, Sung Sook Lee, A. Drilon, 2020, Clinical Cancer Research.

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer

Min Hwan Kim, You Won Lee, Jae Woo Choi, 2019, EMBO molecular medicine.

Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC.

S. Heo, S. Lim, B. Cho, 2020, Cancer discovery.

Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer

S. Lim, B. Cho, H. Shim, 2020, Journal for ImmunoTherapy of Cancer.

YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer

Ho-Juhn Song, Soyoung Kim, B. Cho, 2019, Clinical Cancer Research.

Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma

S. Heo, S. Lim, B. Cho, 2021, Clinical Cancer Research.

Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma

S. Heo, B. Cho, H. Kim, 2019, Scientific Reports.

Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4‐ALK–Positive Human Non–Small Cell Lung Cancer

Sang Gyun Kim, S. Lim, B. Cho, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models

You Won Lee, S. Heo, S. Lim, 2021, Clinical & translational immunology.

Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robustin vivoantitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)

K. Hoeflich, S. Lim, B. Cho, 2021, Experimental and Molecular Therapeutics.

Identification of TRE‐130 as Reversible Inhibitor of Pan‐EGFR Mutants while Sparing EGFR Wild‐Type Activity

B. Cho, Byungho Lim, C. Chae, 2019, Bulletin of the Korean Chemical Society.